日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Research Progress on the Mechanism and Targeted Intervention of G Protein-Coupled Bile Acid Receptor 1 (GPBAR1)-Mediated "Inflammation-Apoptosis-Metabolism-Microcirculation" Regulatory Network in Hepatitis B-Associated Liver Failure

乙型肝炎相关肝衰竭中G蛋白偶联胆汁酸受体1（GPBAR1）介导的“炎症-凋亡-代谢-微循环”调控网络机制及靶向干预的研究进展

期刊:Drug Design Development and Therapy
影响因子:5.1
doi:10.2147/DDDT.S573597
Cui, Chao; Sun, Yu; Zhang, Kaiyue; Shi, Jingfei; Wang, Kai; Gao, Shuai
凋亡
炎症
表观遗传
Apoptosis
炎症/感染
信号转导
Immunology/Inflammation
心血管
代谢
肝衰竭
毒理研究
肝炎
发表日期：2026
文献求助 收藏

Targeting the Golgi apparatus enhances PD-L1 blockade and synergizes with oxaliplatin to improve immunotherapy efficacy

靶向高尔基体可增强PD-L1阻断作用，并与奥沙利铂产生协同效应，从而提高免疫疗法的疗效。

期刊:Journal of Biological Chemistry
影响因子:3.9
doi:10.1016/j.jbc.2026.111343
Li, Haohuan; Cui, Chao; Sun, Chenglu; Chen, Ziyu; Gao, Dengfeng; Yuan, Peng; Tian, Shibo; Zhong, Qin; Xu, Funeng; Liang, Xiaoxia; Jin, Long; Long, Keren; Lu, Lu; Deng, Juan; Cao, Jiaxue; Fan, Xiaolan; Kong, Fanli; Wang, Chengdong; Li, Desheng; Qian, Zhiyong; Li, Mingzhou
PD-L1
免疫/内分泌
发表日期：2026
文献求助 收藏

Selinexor enhances the sensitivity of hepatocellular carcinoma cells to sorafenib by regulating the BAX/Bcl-2/PUMA apoptotic pathway and the XPO1/p27 cell cycle pathway

Selinexor通过调节BAX/Bcl-2/PUMA凋亡通路和XPO1/p27细胞周期通路，增强肝细胞癌细胞对索拉非尼的敏感性。

期刊:Frontiers in Oncology
影响因子:3.3
doi:10.3389/fonc.2026.1762822
Du, Shenghong; Wang, Ling; Chen, Chen; Sun, Yu; Liu, Qian; Shi, Jingfei; Zhang, Feng; Wang, Kai; Cui, Chao
Bcl-2
肿瘤
凋亡
表观遗传
肿瘤免疫
信号转导
细胞生物学
BAX
发表日期：2026
文献求助 收藏

Tuning the efficiency of molecular probes via quinone methide-based in situ labeling

通过基于醌甲基的原位标记调节分子探针的效率

期刊:RSC Chemical Biology
影响因子:3.1
doi:10.1039/d5cb00138b
Rabinowitz, Zachary; Anvar, Seyedehalaleh; Liu, Jun; Chen, Zixin; Zhang, Yuzhao; Cui, Chao; Sigler, Ashton; Cui, Lina
发表日期：2026
文献求助 收藏

[Electric-field modeling, simulation, and experimental analysis of multi-target temporal interference transcranial alternating current stimulation]

[多靶点时域干扰经颅交流电刺激的电场建模、仿真和实验分析]

期刊:Shengwu Yixue Gongchengxue Zazhi/Journal of Biomedical Engineering
影响因子:
doi:10.7507/1001-5515.202601056
Wang, Tingyu; Cui, Chao; Wei, Yujia; Ji, Xiang; Xu, Guizhi
发表日期：2026
文献求助 收藏

Systematic meta-analysis of the toxicities and side effects of the targeted drug lenvatinib

对靶向药物乐伐替尼的毒性和副作用进行系统性荟萃分析

期刊:
影响因子:
doi:10.1080/07853890.2025.2598935
Liu, Huihui; Wang, Kai; Sun, Yu; Li, Qingwei; Shi, Jingfei; Gao, Shuai; Cui, Chao
毒理研究
发表日期：2026
文献求助 收藏

Preclinical advances and mechanistic insights of CAR-T therapy for acute myeloid leukemia: from target iteration to microenvironment regulation

CAR-T疗法治疗急性髓系白血病的临床前研究进展及机制解析：从靶点迭代到微环境调控

期刊:
影响因子:
doi:10.1080/07853890.2026.2640457
Xiao, Yang; Liu, Long; Liu, Shumei; Wang, Lijing; Tian, Jinfeng; Shao, Ziyi; Shi, Jingfei; Cui, Chao
白血病
信号转导
发表日期：2026
文献求助 收藏

Urokinase-type plasminogen activator deficiency enhances CD8+ T cell infiltration and anti-PD-1 therapy efficacy in prostate cancer

尿激酶型纤溶酶原激活剂缺乏可增强前列腺癌中 CD8+ T 细胞的浸润和抗 PD-1 疗法的疗效

期刊:Frontiers in Immunology
影响因子:5.7
doi:10.3389/fimmu.2025.1625226
Xiaoyi Li,Xiao Zhang,Xing Fu,Hong Wu,Xinyu Ye,Xin Huang,Yuhao Cui,Chao-Nan Qian,Yi Lu,Jian Zhang
前列腺癌
细胞生物学
肿瘤
CD8
PD-1
发表日期：2025
文献求助 收藏

From C481 Resistance Evasion to Platelet Preservation: Rilzabrutinib Redefines ITP Targeted Therapy

从逃避C481耐药性到保护血小板：利扎替尼重新定义ITP靶向治疗

期刊:Drug Design Development and Therapy
影响因子:5.1
doi:10.2147/DDDT.S543620
Liu, Long; Xiao, Yang; Jia, Yanyan; Shao, Ziyi; Shi, Jingfei; Cui, Chao
血小板
发表日期：2025
文献求助 收藏

Development and Validation of a Predictive Model for HBsAg Seroclearance After Peg-IFN-Based Therapy: A Multicentre Study

聚乙二醇干扰素治疗后乙肝表面抗原血清清除预测模型的建立与验证：一项多中心研究

期刊:Drug Design Development and Therapy
影响因子:5.1
doi:10.2147/DDDT.S545700
Liu, Hui-Hui; Jiang, Xue-Mei; Cui, Chao; Zhao, Jing; Xu, Juan; Wang, Si-Kui; Hu, Lei-Hua; Yin, Yan-Ping; Wang, Xiao; Yu, Li-Jun; Xu, Cheng; Zhao, Zheng-Hua; Xing, Yan-Qing; Liu, Yue; Wang, Kai; Gao, Shuai
发表日期：2025
文献求助 收藏